Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of AMD3100 in Combination With Pembrolizumab in Head and Neck Squamous Cell Carcinoma Patients Who Have Progressed on Immune Checkpoint Blockade Therapy

NCT04058145 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT04058145
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04058145 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of AMD3100 in Combination With Pembrolizumab in Head and Neck Squamous Cell Carcinoma Patients Who Have Progressed on Immune Checkpoint Blockade Therapy
Lead sponsor
Massachusetts General Hospital
Phase
Phase 2
Overall status
Withdrawn
Start date
September 30, 2019
Completion date
October 11, 2019
Enrollment
0 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck cancer